Manufacturer reports positive secondary endpoint results from Phase 3 SONICS study of levoketoconazole for Cushing’s syndrome

In the study significant mean improvements from baseline were noted at end of the maintenance phase for acne, hirsutism (females only), and peripheral oedema. The study previously met its primary endpoint of significant normalisation rate of urinary free cortisol at six months.

Source:

Biospace Inc.